Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong
· Delayed Price · Currency is HKD
17.77
-0.03 (-0.17%)
Mar 10, 2026, 1:24 PM HKT
HKG:3378 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Other Revenue | 2.2 | 2.54 |
| Revenue | 2.2 | 2.54 |
| Revenue Growth (YoY) | -13.39% | - |
| Gross Profit | 2.2 | 2.54 |
| Selling, General & Admin | 46.19 | 17.22 |
| Research & Development | 74.72 | 46.66 |
| Operating Expenses | 120.91 | 63.88 |
| Operating Income | -118.71 | -61.34 |
| Interest Expense | -9.38 | -2.28 |
| Interest & Investment Income | 2.92 | 4.13 |
| Currency Exchange Gain (Loss) | 0.94 | - |
| EBT Excluding Unusual Items | -124.23 | -59.5 |
| Gain (Loss) on Sale of Investments | 1.41 | -33.92 |
| Pretax Income | -122.82 | -93.42 |
| Income Tax Expense | -5.9 | -8.26 |
| Earnings From Continuing Operations | -116.92 | -85.16 |
| Minority Interest in Earnings | 1.09 | 9.1 |
| Net Income | -115.83 | -76.06 |
| Net Income to Common | -115.83 | -76.06 |
| Shares Outstanding (Basic) | 11 | 7 |
| Shares Outstanding (Diluted) | 11 | 7 |
| Shares Change (YoY) | 49.83% | - |
| EPS (Basic) | -10.60 | -10.42 |
| EPS (Diluted) | -10.60 | -10.42 |
| Free Cash Flow | -111.1 | -56.23 |
| Free Cash Flow Per Share | -10.16 | -7.71 |
| Gross Margin | 100.00% | 100.00% |
| Operating Margin | -5398.55% | -2416.07% |
| Profit Margin | -5267.39% | -2995.51% |
| Free Cash Flow Margin | -5052.48% | -2214.49% |
| EBITDA | -116.7 | -60.83 |
| D&A For EBITDA | 2.02 | 0.52 |
| EBIT | -118.71 | -61.34 |
Source: S&P Capital IQ. Standard template.
Financial Sources.